On Thursday, February 25th, the Food and Drug Administration is expected to vote on whether to issue an emergency use authorization to Johnson & Johnson’s (J&J) new single-dose COVID-19 vaccine candidate. If approved, it will join the Pfizer-BioNTech and Moderna vaccines in the ongoing rollout across the United States.
As part of the “COVID-19 Vaccines: Asked & Answered” video series in which Penn State faculty experts help educate the community on the latest information related to the COVID-19 vaccine, Suresh Kuchipudi, clinical professor of veterinary and biomedical sciences, explains that, like the Pfizer and Moderna vaccines, the J&J vaccine is backed by years of research and has been shown through rigorous clinical trials to be safe and effective.
“COVID-19 vaccines instruct our bodies to make antibodies against the Spike protein of the virus so when we are subsequently exposed to the virus, these antibodies protect us from being infected,” said Kuchipudi.